The stock of Enzo Biochem, Inc. (NYSE:ENZ) hit a new 52-week high and has $7.48 target or 5.00% above today’s $7.12 share price. The 5 months bullish chart indicates low risk for the $325.28M company. The 1-year high was reported on Nov, 29 by Barchart.com. If the $7.48 price target is reached, the company will be worth $16.26M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 110,605 shares traded hands. Enzo Biochem, Inc. (NYSE:ENZ) has risen 36.49% since April 26, 2016 and is uptrending. It has outperformed by 31.23% the S&P500.
Analysts await Enzo Biochem, Inc. (NYSE:ENZ) to report earnings on December, 5. They expect $-0.05 earnings per share, 0.00% or $0.00 from last year’s $-0.05 per share. After $-0.04 actual earnings per share reported by Enzo Biochem, Inc. for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
According to Zacks Investment Research, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation.”
Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.14, from 1.38 in 2016Q1. The ratio worsened, as 16 funds sold all Enzo Biochem, Inc. shares owned while 24 reduced positions. 25 funds bought stakes while 30 increased positions. They now own 24.06 million shares or 13.07% more from 21.28 million shares in 2016Q1.
Moreover, City Com has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 120 shares. First Light Asset Mgmt Limited Liability last reported 3.78% of its portfolio in the stock. Price T Rowe Assoc Md has invested 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Blackrock Advisors Limited Liability Company reported 19,949 shares or 0% of all its holdings. Spark Inv Mngmt Lc has 0.06% invested in the company for 99,200 shares. Ladenburg Thalmann Fin Services last reported 0% of its portfolio in the stock. Financial Bank Of New York Mellon Corporation holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 187,262 shares. The California-based Fuller & Thaler Asset Mngmt has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Wells Fargo And Communication Mn has 13,978 shares for 0% of their US portfolio. Eagle Advisors Lc holds 0.01% or 62,210 shares in its portfolio. Connor Clark & Lunn Inv Management Ltd, a British Columbia – Canada-based fund reported 58,220 shares. Springbok Capital Management Lc accumulated 13,200 shares or 0.01% of the stock. Clearbridge Investments Limited Liability Co has 329 shares for 0% of their US portfolio. Maple Management reported 14,000 shares or 0.03% of all its holdings. The Massachusetts-based Rhumbline Advisers has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ).
More important recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Prnewswire.com which released: “Lone Star Value Issues Open Letter to Shareholders of Enzo Biochem, Inc.” on December 22, 2015, also Seekingalpha.com published article titled: “Enzo Biochem’s (ENZ) Management on Q4 2016 Results – Earnings Call Transcript”, Businesswire.com published: “Enzo Biochem Releases New Investor Presentation on Corporate Strategy” on November 25, 2015. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) was released by: Businesswire.com and their article: “Enzo Biochem Reaches $10 Million Patent Infringement Settlement with …” with publication date: October 13, 2015.
ENZ Company Profile
Enzo Biochem, Inc. (Enzo), incorporated on August 13, 1976, is a bioscience firm focusing on delivering and applying technology capabilities to produce services and products. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. The Company’s products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets. The Company’s product development activity and pipeline include products, such as HPV E6/E7 Detection, HCV Viral Load, Cardiac Marker, IHC Detection, TH1/TH2, Cancer AB Panel and Cancer Marker Panel. The Firm has developed a portfolio of technologies with a range of research, diagnostic and therapeutic applications. The Company’s technologies include Gene analysis technology, Amplification, Flow Cytometry, Non-radioactive labeling and detection and Formats.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.